PulseAugur
EN
LIVE 16:27:18
中文(ZH) 万邦医药:推进核心管线创新药石杉碱甲控释片等新药合作协议的相关信息均为不实信息

Wanbang Medicine denies false drug deal reports; EU mandates Google open Android AI access

Wanbang Medicine has issued a statement clarifying that recent reports about advancing drug pipelines and signing cooperation agreements for innovative drugs like Shijianjinjia are false. The company's stock experienced significant fluctuations, prompting the clarification. Separately, the European Commission has mandated Google to open up key Android system functionalities to third-party AI assistants and share anonymized search data with third-party search engines under the Digital Markets Act to foster competition. AI

IMPACT EU regulation forces Google to enable third-party AI assistants on Android, potentially increasing competition and user choice in AI services.

RANK_REASON Regulatory action by the European Commission impacting a major tech company's AI and search services, alongside a corporate denial of false information. [lever_c_demoted from significant: ic=1 ai=0.7]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Wanbang Medicine denies false drug deal reports; EU mandates Google open Android AI access

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Wanbang Medicine: Information related to the cooperation agreement for new drugs such as the core pipeline innovative drug Shijianjinjia controlled-release tablets is false.

    36氪获悉,万邦医药公告,公司股票连续2个交易日收盘价格涨幅偏离值累计超过30%,属于异常波动。公司近期关注到有媒体和股吧等股票社区报道称万邦医药推进核心管线创新药石杉碱甲控释片、签订渐冻症等新药合作协议的相关信息均为不实信息;公司2026年半年度业绩情况未对外披露,也暂未发布业绩预告。